Sonia Iyer

AstraZeneca (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index1.0kcitations94works9.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(25), Lung Cancer Treatments and Mutations(18), CRISPR and Genetic Engineering(13), Ovarian cancer diagnosis and treatment(11), PARP inhibition in cancer therapy(11)

Publications94 total

Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial
Gynecologic Oncology·2026
Supp Fig 7 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Table 5 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Fig 9 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Table 3 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Table 4 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Inflammation awakens dormant cancer cells by modulating the epithelial–mesenchymal phenotypic state
Proceedings of the National Academy of Sciences·2025· 1 citedOpen Access
Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study
JTO Clinical and Research Reports·2025Open Access
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer
Cancer Cell·2025· 13 citedOpen Access
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.
Journal of Clinical Oncology·2025· 7 cited
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation
International Journal of Gynecological Cancer·2025· 1 cited
LB002/#1594  Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: exploratory analyses of biomarker/histological heterogeneity and efficacy in the DUO-E mismatch repair proficient subpopulation
2024· 5 cited
Data from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024Open Access
Supplementary Data 1 from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024Open Access
Supplementary Data 1 from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024Open Access
Data from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024Open Access
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
Clinical Cancer Research·2024· 7 citedOpen Access
Abstract 7177: Development and validation of clinical pharmacodynamic biomarkers to assess treatment response to HPK1 inhibition and guide dosing decisions
Cancer Research·2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
Nature Communications·2024· 43 citedOpen Access
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Nature Medicine·2024· 104 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

John V. Heymach(21), Emma Dean(20), Natalie I. Vokes(18), Ana Galan Cobo(18), David Molkentine(18), Margarita Fernandez-Chas(17), Santiago Treviño(17), Vitaly Druker(17), Yu Qian(17), Sonia Patel(17), Stephanie Schmidt(17), Lingzhi Hong(17), Jeff Lewis(17), Waree Rinsurongkawong(17), Vadeerat Rinsurongkawong(17), J. Jack Lee(17), Marcelo V. Negrão(17), Don L. Gibbons(17), Ara A. Vaporciyan(17), Xiuning Le(17)